Generic Pharma Product Market in the USA Discussed in Kuick Research Market Report Now Available at MarketPublishers.com
02 Mar 2016 • by Natalie Aster
LONDON – US regulators are constantly enhancing the current infrastructure for approval of generic drugs. The development of regulations plays a quite important role in achieving higher cost savings without compromising the health of the patients. Thus, the publication known as the Orange Book has been created which lists reference listed drugs (RLDs) and generic drug products approved by the FDA based on effectiveness and safety. Physicians can refer to it before prescribing less expensive alternatives containing the same API. The role of health insurance firms is also being examined in the prescription of generics because they will opt for cheaper alternative with the very same pharmacological efficacy. The developers of generic drugs are likely to benefit from this scenario by way of promoting their medicines as patient-friendly solutions.
Generics have emerged as an essential part of the US pharma industry. Meantime, a number of critics have raised concerns over surging commercialisation of generic meds. Developers of novel drug products are heavily investing in R&D, and the currently available generics are poised to compete with the developers’ products in the same category, thus resulting in the loss of market shares. This situation is likely to lead to the aversion amid pharma product developers resulting in lesser innovation and launch of costly drugs. Balance between developers’ rights and earnings need to be achieved by regulators in the years to come.
Insightful report “US Generic Drug Market Opportunity Outlook 2020” created by Kuick Research takes a detailed look at the US market for generic drugs. It gives an overview of the performance of the US generic drugs market and sheds light on the advances in the sector; offers information on the so-called Hatch-Waxman Act along with revealing its implications; covers the FDA’s review on generic drugs; discusses supportive features of the country’s generic drug laws; methods to achieve greater cost arbitrage by generic drugs; looks into the market scenario of generic and branded drugs domestically; unveils the effects of generic drug imports on US economy; describes the role of online pharmacies in the growth of the national generic drugs sector. The report canvases the market dynamics, covers commercialisation challenges, profiles key diseases in the USA, competitive landscape covering the 26 companies, and casts light on the future prospects of the US generic drugs market.
US Generic Drug Market Opportunity Outlook 2020
Published: February, 2016
Price: US$ 1,500.00
More studies by the publisher can be found at Kuick Research page.